| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.05 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.064 | 0.05 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.06 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.098 | 0.06 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.055 | 0.07 |